论文部分内容阅读
目的评价普米克气雾剂联合孟鲁司特治疗小儿哮喘的临床效果。方法选择本院在2014年3月至2016年9月间收治的104例小儿哮喘患者作为研究主体。分成A组和B组,每组52例。A组给予普米克气雾剂联合孟鲁司特治疗,B组给予单纯的普米克气雾剂治疗。对比两组的治疗效果、不良反应率与肺功能改善情况。结果 A组的治疗总有效率是96.15%,B组是86.54%,对比差异明显,有统计学意义(P<0.05)。A组的不良反应率是3.85%,B组是5.77%,对比无差异,无统计学意义(P>0.05)。A组的FEV1(1秒用力呼气容量)、PEF(峰值呼气流速)与肺部体征消退时间均优于B组,对比有差异,有统计学意义(P<0.05)。结论对于小儿哮喘疾病,采用普米克气雾剂联合孟鲁司特治疗,能够显著改善患儿的肺功能,不良反应少,疗效确切,值得推广。
Objective To evaluate the clinical efficacy of Pulmicort aerosol combined with montelukast in the treatment of pediatric asthma. Methods 104 cases of pediatric asthma admitted to our hospital from March 2014 to September 2016 were selected as the research subjects. Divided into A group and B group, 52 cases in each group. Group A was given Pulmicort aerosol combined with montelukast, and Group B was treated with pure Pulmicort aerosol. Compare the two groups of treatment effect, adverse reaction rate and pulmonary function improvement. Results The total effective rate of treatment group A was 96.15%, while that of group B was 86.54%. The difference was statistically significant (P <0.05). The adverse reaction rate of group A was 3.85%, while that of group B was 5.77%. There was no significant difference between group A and group B (P> 0.05). The FEV1 (forced expiratory volume in 1 second), PEF (peak expiratory flow rate) and lung subsidence time in group A were all better than those in group B, with significant difference (P <0.05). Conclusions Pulmicort aerosol combined with montelukast can significantly improve children’s lung function, with fewer adverse reactions and definite curative effect, which is worthy of promotion in pediatric asthma.